FDA approves second strength of trastuzumab biosimilar Hercessi

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

FDA approves second strength of trastuzumab biosimilar Hercessi

Biosimilares/Novedades | Posted 23/10/2024 0 Post your comment

On 18 September 2024, the US Food and Drug Administration (FDA) granted approval for a second strength for Accord’s Hercessi (trastuzumab-strf), a biosimilar referencing Roche’s Herceptin.

Hercessi is now approved in a 420 mg strength to treat HER2-overexpressing breast and gastric or gastroesophageal junction adenocarcinoma. This news comes after the FDA approval of a 150 mg strength on 29 April 2024 [1].

The FDA’s approval of a second strength of Hercessi paves the way for Accord BioPharma to commercially launch its first biosimilar in the US in early 2025.

FDA approval for Hercessi was based on analytical, preclinical, and clinical data from three studies, showing it is similar to Herceptin (trastuzumab) in efficacy, safety, and quality. These included two Phase 1 pharmacokinetic (PK) studies in healthy volunteers (HLX02-HV01, HLX02-HV02) and a Phase 3 clinical study in patients with HER2-overexpressing metastatic breast cancer (HLX02-BC01). The data adhered to FDA biosimilar guidelines and showed no clinically meaningful differences in safety or efficacy between HERCESSI and Herceptin, supporting their biosimilarity.

Hercessi (HLX02) was originally developed by Accord's business partner, Shanghai Henlius Biotech, Inc, headquartered in Shanghai, China. In 2021, Henlius granted Accord BioPharma the exclusive rights to develop and commercialize Hercessi in the US and Canada.

Henlius’ trastuzumab biosimilar, Adheroza, was approved in Canada on 22 August 2024, and is also marketed by Accord [2].

Accord BioPharma, the US specialty division of Intas Pharmaceuticals Ltd, is focused on the development of oncology, immunology, and critical care therapies.

LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View the latest headline article: Un innovador acuerdo de compra directa permite reducir drásticamente los precios de los biosimilares de adalimumab

Browse the news in the Latin American Forum!

FORO LATINOAMERICANO
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Ver el último artículo de cabecera: Un innovador acuerdo de compra directa permite reducir drásticamente los precios de los biosimilares de adalimumab

!Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.

References
1. GaBI Online - Generics and Biosimilars Initiative. FDA approves ustekinumab, trastuzumab, and tocilizumab biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Oct 23]. Available from: www.gabionline.net/biosimilars/news/fda-approves-ustekinumab-trastuzumab-and-tocilizumab-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. Canada approves trastuzumab Adheroza and ustekinumab Steqeyma biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2024 Oct 23]. Available from: www.gabionline.net/biosimilars/news/canada-approves-trastuzumab-adheroza-and-ustekinumab-steqeyma-biosimilars

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.